![Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial - Cancer Therapy Advisor Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial - Cancer Therapy Advisor](https://www.cancertherapyadvisor.com/wp-content/uploads/sites/12/2018/12/pancreaticcancercystsmanage_747744.jpg)
Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial - Cancer Therapy Advisor
![A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial) | SpringerLink A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1245%2Fs10434-022-11917-2/MediaObjects/10434_2022_11917_Figa_HTML.png)
A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial) | SpringerLink
![PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications | Molecular Cancer | Full Text PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications | Molecular Cancer | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12943-020-01167-9/MediaObjects/12943_2020_1167_Fig2_HTML.png)
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications | Molecular Cancer | Full Text
![Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib - Annals of Oncology Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/2ee8df0a-1279-4d12-9291-1108349ac2d1/gr1.jpg)
Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib - Annals of Oncology
![Phase III POLO Trial - Capsule Summary Slidesets - GI Cancers - 2019 ASCO Annual Meeting - Oncology - Clinical Care Options Phase III POLO Trial - Capsule Summary Slidesets - GI Cancers - 2019 ASCO Annual Meeting - Oncology - Clinical Care Options](https://www.clinicaloptions.com/-/media/oncology/conferences/clin-onc-june-2019/gastrointestinal-cancers/cco_clin_onc_june_2019_lba4_thumb.png?rev=5177ee280f4c49f9a00685b0b5ba2915&h=166&w=295&la=en&hash=945B75320007694151EBF43C0510C5DF0C20B4FB)
Phase III POLO Trial - Capsule Summary Slidesets - GI Cancers - 2019 ASCO Annual Meeting - Oncology - Clinical Care Options
![PDF) Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial PDF) Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial](https://i1.rgstatic.net/publication/347645800_Cost-Effectiveness_Analysis_of_Maintenance_Olaparib_in_Patients_with_Metastatic_Pancreatic_Cancer_and_a_Germline_BRCA12_Mutation_Based_on_the_POLO_Trial/links/600fed61a6fdccdcb87f4890/largepreview.png)
PDF) Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial
![FacingOurRisk on Twitter: "POLO: a study for pple w/pancreatic cancer & BRCA mutation olaparib (a PARP inhibitor) as maintenance therapy. https://t.co/ud1DOTbQJJ https://t.co/1s6t8fkFVH" / Twitter FacingOurRisk on Twitter: "POLO: a study for pple w/pancreatic cancer & BRCA mutation olaparib (a PARP inhibitor) as maintenance therapy. https://t.co/ud1DOTbQJJ https://t.co/1s6t8fkFVH" / Twitter](https://pbs.twimg.com/media/DKpwxkAW4AEbaD_.png)
FacingOurRisk on Twitter: "POLO: a study for pple w/pancreatic cancer & BRCA mutation olaparib (a PARP inhibitor) as maintenance therapy. https://t.co/ud1DOTbQJJ https://t.co/1s6t8fkFVH" / Twitter
![Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not](https://pbs.twimg.com/media/D8FZZTVXYAMy4aQ.jpg)
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
![Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy](https://larvolclin.s3.us-west-2.amazonaws.com/resize_1624271596134696133960d06aec8d2d6.png)